3Andreu G,Morel P,Forestier F,et al.Hemovigilance network in France:organization and analysis of immediate transfusion incident reports from 1994 to 1998[J].Transfusion,2002,42(10):1356
4Rebibo D,Hauser L,Slimani A,et al.The French Haemovigilance System:organization and results for 2003[J].Transfus Apher Sci,2004,31(2):145
6Stainsby D.ABO incompatible transfusions-experience from the UK Serious Hazards of Transfusion (SHOT) scheme transfusions ABO incompatible[J].Transfus Clin Biol,2005,12(5):385
7Dzik WH,Murphy MF,Andreu G,et al.An international study of the performance of sample collection from patients[J].Vox Sang,2003,85(1):40
8Dzik WH.Emily Cooley Lecture 2002:transfusion safety in the hospital[J].Transfusion,2003,43(9):1190
9Novis DA,Miller KA,Howanitz PJ,et al.Audit of transfusion procedures in 660 hospitals[J].Arch Pathol Lab Med,2003,127(5):541
10Dohnalek LJ,Cusaac L,Westcott J,et al.The code to safer transfusions[J].Nurs Manage,2004,35(6):33
4Hsu HM, Lu CF, Lee SC, et al. Seroepidemiology surey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immuination. J Infect Dis, 1999,179:367-370.
5WHO.Hepatitis B surface antigen assay: operational characteristics.2000.1-15.
6Norihiro F,Jun H,Yasunori S.The elimination Of hepatitis B virus infection:changing seroepidemiology of hepatitis A and B virus infection in Okinawa Japan over a 26-year period Am J Med Hyp,1998.59:693—698.
